SCHEMBL6346404

SCHEMBL6346404

CC(=O)Nc1ccc2c(c1)CCC(CO)O2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 1/20 0.51
ITGA2B P08514 1/20 0.51
CYP1A2 P05177 2/20 0.47
CYP2C19 P33261 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MTNR1A P48039 1/20 0.45
CYP2D6 P10635 1/20 0.44
OPRK1 P41145 1/20 0.44
MAPT P10636 3/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
BAZ2B Q9UIF8 1/20 0.43
AAK1 Q2M2I8 1/20 0.42
CHRNB4 P30926 2/20 0.41
CHRNA3 P32297 2/20 0.41
GAA P10253 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ADRA2A P08913 1/20 0.41
MAOA P21397 1/20 0.41
SLC6A2 P23975 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6345014 0.87 ITGB3 (0.66) ITGB3ITGA2BCYP1A2CYP2C19NPSR1
SCHEMBL6307140 0.87 ITGB3 (0.66) ITGB3ITGA2BCYP1A2CYP2C19NPSR1
SCHEMBL6354383 0.85 ITGB3 (0.47) ITGB3ITGA2BCYP1A2CYP2C19NPSR1
SCHEMBL6493264 0.82 CYP1A2 (0.50) ITGB3ITGA2BCYP1A2CYP2C19NPSR1
SCHEMBL6748594 0.82 ITGB3 (0.50) ITGB3ITGA2BCYP1A2CYP2C19NPSR1
SCHEMBL6346160 0.82 ITGB3 (0.50) ITGB3ITGA2BCYP1A2CYP2C19NPSR1
SCHEMBL5847418 0.80 CYP2D6 (0.52) ITGB3ITGA2BCYP1A2CYP2C19NPSR1
SCHEMBL5847422 0.80 CYP2D6 (0.52) ITGB3ITGA2BCYP1A2CYP2C19NPSR1
SCHEMBL5847426 0.80 CYP2D6 (0.52) ITGB3ITGA2BCYP1A2CYP2C19NPSR1
SCHEMBL10509308 0.79 CYP1A2 (0.47) ITGB3ITGA2BCYP1A2CYP2C19NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6903227-B2 Synthesis of 2-acyl substituted chromanes and intermediates thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-06-07 US disclosed
US-20040044225-A1 Chiral and achiral synthesis of 2-acyl substituted chromanes and their derivatives MILLENNIUM PHARMACEUTICALS, INC. 2004-03-04 US disclosed
US-20030233002-A1 Synthesis of 2-Acyl substituted chromanes and intermediates thereof MILLENNIUM PHARMACEUTICALS, INC. 2003-12-18 US disclosed
WO-2001092249-A2 CHIRAL AND ACHIRAL SYNTHESIS OF 2-ACYL SUBSTITUTED CHROMANES AND THEIR DERIVATIVES COR THERAPEUTICS, INC. (US) 2001-12-06 WO disclosed
WO-2001092250-A2 SYNTHESIS OF 2-ACYL SUBSTITUTED CHROMANES AND INTERMEDIATES THEREOF COR THERAPEUTICS, INC. (US) 2001-12-06 WO disclosed
EP-0145067-B1 DERIVATIVES OF 2,2'-IMINOBISETHANOL JANSSEN PHARMACEUTICA N.V. (BE) 1989-01-25 EP disclosed
US-4654362-A CARDIOVASCULAR DISORDERS JANSSEN PHARMACEUTICA, N.V. (BE) 1987-03-31 US disclosed
EP-0145067-A2 Derivatives of 2,2'-iminobisethanol JANSSEN PHARMACEUTICA N.V. (BE) 1985-06-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030233002-A1 Synthesis of 2-Acyl substituted chromanes and intermediates thereof PLA2G7, PAFAH1B2, PAFAH1B3 ITGB3 1014/4885ITGA2B 678/4885CYP1A2 198/4885
US-20040044225-A1 Chiral and achiral synthesis of 2-acyl substituted chromanes and their derivatives ACAT2, ACACA, COASY ITGB3 203/4885ITGA2B 395/4885CYP1A2 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.